Peter Robert Rose
Pfizer
39 Papers
136 Citations
Peter Robert Rose is an academic researcher from Pfizer. The author has contributed to research in topics: Ring (chemistry) & Anhydrous. The author has an hindex of 9, co-authored 39 publications.
Chat about Author
Papers
Evaluation of Kilogram-Scale Sonagashira, Suzuki, and Heck Coupling Routes to Oncology Candidate CP-724,714
David H. Brown Ripin,Dennis E. Bourassa,Thomas Andrew Brandt,Michael J. Castaldi,Heather N. Frost,Joel M. Hawkins,Phillip J. Johnson,Stephen S. Massett,Karin Neumann,James E. Phillips,Jeffery W. Raggon,Peter Robert Rose,Jennifer Lea Rutherford,Barbara J. Sitter,A. Morgan Stewart,Michael G. Vetelino,Lulin Wei +16 more
TL;DR: In this article, a convergent and selective synthesis of the anti-cancer compound 2-methoxy-N-(3-{4]-3-methyl-4-(6methyl-pyridin-3-yloxy)phenylamino]quinazolin-6-yl}-E-allyl)acetamide (CP-724,714) was described.
76
Synthesis of trovafloxacin using various (1α,5α,6α)-3-azabicyclo[3.1.0]hexane derivatives
Timothy Norris,Braish Tamim F,Michael Butters,Devries Keith Michael,Joel M. Hawkins,Stephen S. Massett,Peter Robert Rose,Dinos Santafianos,Constantine Sklavounos +8 more
TL;DR: In this paper, the prototype of the industrial synthesis of this ring system and possible mechanistic pathways to exclusive formation of the exo or 6α-nitro derivative of trovafloxacin were described.
24
Development of two synthetic routes to CE-178,253, a CB1 antagonist for the treatment of obesity
Thomas Andrew Brandt,Stephane Caron,David B. Damon,Joseph DiBrino,Arun Ghosh,David A. Griffith,Sandeep Kedia,John A. Ragan,Peter Robert Rose,Brian C. Vanderplas,Lulin Wei +10 more
TL;DR: In this article, two synthesized versions of CB1 antagonist CE-178,253 benzenesulfonate are described, one based on the discovery synthesis and the other based on condensation of a bromoketone with substituted thiosemicarbazide.
23
Development of a Practical and Efficient Synthesis of CP-945,598-01, a CB1 Antagonist for the Treatment of Obesity
John A. Ragan,Dennis E. Bourassa,Jon Blunt,Darragh Breen,Busch Frank R,Eric M. Cordi,David B. Damon,Nga M. Do,Alanya Engtrakul,Denis Lynch,Ruth E. McDermott,Joseph A. Mongillo,Maria M. O’Sullivan,Peter Robert Rose,Brian C. Vanderplas +14 more
TL;DR: In this article, an efficient bond-forming sequence and optimization of reaction conditions are described for the synthesis of CP-945,598-01 (1·HCl), a CB1 antagonist in clinical studies for the treatment of obesity.
16